Founded in 2007 by Fusion IP and based on discoveries from the University
of Sheffield laboratories of Professor Simon Foster & Dr Jorge Garcia-Lara,
Absynth is a private, UK biotechnology company focused on the discovery and
development of products for the prevention and treatment of bacterial
infections. The company’s distinctive approach uses genomics to identify
highly conserved bacterial protein targets, essential for life and capable
of stimulating the immune system.
The company's platform has broad potential against a range of bacterial
infections. Absynth’s novel targets offer two lines of attacking infection:
vaccines for prophylactic use to stimulate an immune response or antibodies
for anti-infective treatments. In its vaccine programmes, the company has
shown that its S. aureus antigens effectively harness the immune
system and in vivo reproducibly protect against infection in the
gold-standard in vivo model of infection. Absynth’s novel antigens are also
found in other infectious bacteria which forms the basis of the company’s
pipeline. Absynth is located in Sheffield, UK.